Showing 1841-1850 of 2652 results for "".
- Genentech/Roche Complete Enrollment in YOSEMITE and RHINE Phase 3 Studies of Faricimab in DMEhttps://modernod.com/news/genentech-roche-complete-enrollment-in-yosemite-and-rhine-phase-3-studies-of-faricimab-in-dme/2476957/Genentech and Roche announced they have completed patient enrollment in the phase 3 YOSEMITE (
- Report: Chocolate May Not Help Your Visionhttps://modernod.com/news/report-chocolate-may-not-help-your-vision/2476938/In disappointing news for chocolate lovers, researchers have found that contrary to an earlier report, eating dark chocolate will not improve your vision, according to a Reuters report. The earlier report suggested that certain aspects of
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the
- Second Sight Announces $2.4 Million, 4-Year Grant from NIH to Develop Spatial Localization and Mapping Technologyhttps://modernod.com/news/second-sight-announces-2-4-million-4-year-grant-from-nih-to-develop-spatial-localization-and-mapping-technology/2476926/Second Sight Medical Products announced receipt of a $2.4 million, 4-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is i
- EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-yutiq-presentations-at-aao-annual-meeting/2476921/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Aca
- Cataract Surgery Products Continue to be the Main Single-Use Surgical Device Sales Driverhttps://modernod.com/news/cataract-surgery-products-continue-to-be-the-main-single-use-surgical-device-sales-driver/2476905/The world’s aging population—leading to steady growth in cataract surgeries—and rising concerns over cross-contamination are key factors that will drive healthy growth in the single-use ophthalmic surgical product mar
- EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-retina-society-scientific-meeting/2476859/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 5
- Study: Yellow Lens Glasses Don’t Improve Drivers’ Night Visionhttps://modernod.com/news/study-yellow-lens-glasses-dont-improve-drivers-night-vision/2476789/Touted to improve nighttime eyesight, yellow lens glasses don’t help drivers see better and may, in fact, worsen vision, a new study suggests, Reuters Health reported. Researchers found that yellow-lens wearing volunteers ope
- Doctor Alexa Will See You Now: Is Amazon Primed To Come To Your Rescue?https://modernod.com/news/doctor-alexa-will-see-you-now-is-amazon-primed-to-come-to-your-rescue/2476782/Now that it’s upending the way you play music, cook, shop, hear the news and check the weather, the friendly voice emanating from your Amazon Alexa-enabled smart speaker is poised to wriggle its way into all things health care. Amazon has big ambitions for its devices, according to a
- EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code for Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-early-assignment-of-permanent-and-specific-j-code-for-yutiq/2476769/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code, J7314, through the Healthcare Common Procedure Coding System (HCPCS) for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micr